The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In the prospective study by Flowers et al. (2008) in patients with steroid-refractory/dependent/intolerant cGvHD who were treated with ECP, which sites showed significant improvement in extracutaneous cGvHD at Weeks 12 and 24?
A
B
C
D
Video series
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).
Here, we share the presentation by Florent Malard, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, that explored early intervention and ECP-based combinations. Mallard covered use of ECP first-line, as well as ECP combinations in patients with steroid-refractory and steroid-dependent cGvHD, including recent approvals and findings from clinical trials.
Listen to this presentation as a podcast here:
Symposium | Early intervention and use of ECP combinations in cGvHD
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their thoughts on how ECP can affect lymphocyte count during and after treatment.
Symposium | Q&A | How ECP can affect lymphocyte count during and after treatment?
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content